Difference between revisions of "Team:Tuebingen"
| (3 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
<meta charset="UTF-8" content="width=device-width, initial-scale=1.0"/> | <meta charset="UTF-8" content="width=device-width, initial-scale=1.0"/> | ||
| + | <style> | ||
| + | /* Paste this css to your style sheet file or under head tag */ | ||
| + | /* This only works with JavaScript, | ||
| + | if it's not present, don't show loader */ | ||
| + | .js #loader { | ||
| + | display: block; | ||
| + | position: absolute; | ||
| + | left: 100px; | ||
| + | top: 0; | ||
| + | } | ||
| + | |||
| + | .se-pre-con { | ||
| + | position: fixed; | ||
| + | left: 0px; | ||
| + | top: 0px; | ||
| + | width: 100%; | ||
| + | height: 100%; | ||
| + | z-index: 9999; | ||
| + | background: #292935; | ||
| + | } | ||
| + | |||
| + | .se-pre-con img { | ||
| + | width: 40%; | ||
| + | height: 40%; | ||
| + | margin-left: 30%; | ||
| + | margin-top: 15%; | ||
| + | } | ||
| + | |||
| + | @media screen and (min-width: 1500px ) { | ||
| + | .se-pre-con img { | ||
| + | margin-top: 20%; | ||
| + | width: 25%; | ||
| + | height: 15%; | ||
| + | margin-left: 35%; | ||
| + | } | ||
| + | } | ||
| + | |||
| + | @media screen and (max-width: 1100px ) { | ||
| + | .se-pre-con img { | ||
| + | margin-top: 20%; | ||
| + | height: 30%; | ||
| + | width: 50%; | ||
| + | margin-left: 25%; | ||
| + | } | ||
| + | } | ||
| + | |||
| + | @media screen and (max-width: 700px ) { | ||
| + | .se-pre-con img { | ||
| + | margin-top: 18%; | ||
| + | height: 20%; | ||
| + | } | ||
| + | } | ||
| + | </style> | ||
| + | </head> | ||
| + | <body> | ||
| + | <div class="se-pre-con"> | ||
| + | <img src="https://2019.igem.org/wiki/images/4/49/T--Tuebingen--DNA_gif.gif"> | ||
| + | </div> | ||
| + | <script src="https://2019.igem.org/Team:Tuebingen/jqueryLoadJS?action=raw&ctype=text/javascript"></script> | ||
| + | <script src="https://2019.igem.org/Team:Tuebingen/jmodernizerJS?action=raw&ctype=text/javascript"></script> | ||
| + | <script> | ||
| + | $(window).load(function () { | ||
| + | setTimeout(removeLoader, 1000); | ||
| + | }); //wait for page load PLUS one seconds. | ||
| + | function removeLoader() { | ||
| + | $(".se-pre-con").fadeOut(500, function () { | ||
| + | // fadeOut complete. Remove the loading div | ||
| + | $(".se-pre-con").remove(); //makes page more lightweight | ||
| + | }); | ||
| + | } | ||
| + | </script> | ||
| + | </body> | ||
<style> | <style> | ||
/*! | /*! | ||
| Line 9,707: | Line 9,779: | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Description</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Description</a> | ||
<a class="dropdown-item" href="/Team:Tuebingen/Killswitch" | <a class="dropdown-item" href="/Team:Tuebingen/Killswitch" | ||
| − | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Kill | + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Kill Switch</a> |
| − | + | ||
<a class="dropdown-item" href="/Team:Tuebingen/Nissle" | <a class="dropdown-item" href="/Team:Tuebingen/Nissle" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Nissle</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Nissle</a> | ||
<a class="dropdown-item" href="/Team:Tuebingen/Incretin" | <a class="dropdown-item" href="/Team:Tuebingen/Incretin" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Incretin</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Incretin</a> | ||
| + | <a class="dropdown-item" href="/Team:Tuebingen/Model" | ||
| + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Model</a> | ||
| + | <a class="dropdown-item" href="/Team:Tuebingen/Software" | ||
| + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Software</a> | ||
<a class="dropdown-item" href="/Team:Tuebingen/Results" | <a class="dropdown-item" href="/Team:Tuebingen/Results" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Results</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Results</a> | ||
| Line 9,719: | Line 9,794: | ||
<a class="dropdown-item" href="/Team:Tuebingen/Notebook" | <a class="dropdown-item" href="/Team:Tuebingen/Notebook" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Notebook</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Notebook</a> | ||
| − | |||
| − | |||
| − | |||
| − | |||
<a class="dropdown-item" href="/Team:Tuebingen/Outlook" | <a class="dropdown-item" href="/Team:Tuebingen/Outlook" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Outlook</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Outlook</a> | ||
| Line 9,743: | Line 9,814: | ||
<a class="dropdown-item" href="/Team:Tuebingen/Improved_Part" | <a class="dropdown-item" href="/Team:Tuebingen/Improved_Part" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Improved | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Improved | ||
| + | Parts</a> | ||
| + | <a class="dropdown-item" href="/Team:Tuebingen/Characterized_Part" | ||
| + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Characterized | ||
Parts</a> | Parts</a> | ||
<a class="dropdown-item" href="/Team:Tuebingen/Composite_Part" | <a class="dropdown-item" href="/Team:Tuebingen/Composite_Part" | ||
| Line 9,765: | Line 9,839: | ||
<a class="dropdown-item" href="/Team:Tuebingen/Collaborations" | <a class="dropdown-item" href="/Team:Tuebingen/Collaborations" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Collaborations</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Collaborations</a> | ||
| − | |||
| − | |||
<a class="dropdown-item" href="/Team:Tuebingen/Sponsors" | <a class="dropdown-item" href="/Team:Tuebingen/Sponsors" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Sponsors</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Sponsors</a> | ||
| + | <a class="dropdown-item" href="/Team:Tuebingen/Attributions" | ||
| + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Attributions</a> | ||
<a class="dropdown-item" href="/Team:Tuebingen/Gallery" | <a class="dropdown-item" href="/Team:Tuebingen/Gallery" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Gallery</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Gallery</a> | ||
| Line 9,783: | Line 9,857: | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Overview</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Overview</a> | ||
<a class="dropdown-item" href="/Team:Tuebingen/Public_Engagement" | <a class="dropdown-item" href="/Team:Tuebingen/Public_Engagement" | ||
| − | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Education | + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Education & Public Engagement</a> |
| − | + | ||
| − | + | ||
<a class="dropdown-item" href="/Team:Tuebingen/Experts" | <a class="dropdown-item" href="/Team:Tuebingen/Experts" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Experts</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Experts</a> | ||
<a class="dropdown-item" href="/Team:Tuebingen/SDG" | <a class="dropdown-item" href="/Team:Tuebingen/SDG" | ||
| − | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Sustainable | + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Sustainable Development Goals</a> |
| − | + | ||
| − | + | ||
<a class="dropdown-item" href="/Team:Tuebingen/Experimenta" | <a class="dropdown-item" href="/Team:Tuebingen/Experimenta" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Experimenta | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Experimenta | ||
| − | Science | + | Science Center</a> |
| − | + | ||
<a class="dropdown-item" href="/Team:Tuebingen/Survey" | <a class="dropdown-item" href="/Team:Tuebingen/Survey" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Survey</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Survey</a> | ||
| Line 9,807: | Line 9,876: | ||
<div class="dropdown-menu"> | <div class="dropdown-menu"> | ||
<a class="dropdown-item" href="/Team:Tuebingen/Human_Practices" | <a class="dropdown-item" href="/Team:Tuebingen/Human_Practices" | ||
| − | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Integrated | + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Integrated Human Practise</a> |
| − | + | ||
<a class="dropdown-item" href="/Team:Tuebingen/Public_Engagement" | <a class="dropdown-item" href="/Team:Tuebingen/Public_Engagement" | ||
| − | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Education | + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Education & Public Engagement</a> |
| − | + | ||
| − | + | ||
<a class="dropdown-item" href="/Team:Tuebingen/Entrepreneurship" | <a class="dropdown-item" href="/Team:Tuebingen/Entrepreneurship" | ||
| − | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Supporting | + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Supporting Entrepreneurship</a> |
| − | + | ||
| − | + | ||
| − | + | ||
<a class="dropdown-item" href="/Team:Tuebingen/Model" | <a class="dropdown-item" href="/Team:Tuebingen/Model" | ||
style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Model</a> | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">Model</a> | ||
| Line 9,832: | Line 9,895: | ||
<li class="nav-item mx-3"> | <li class="nav-item mx-3"> | ||
<a class="nav-link" href="https://igem.org/2019_Judging_Form?team=Tuebingen" target="_blank" | <a class="nav-link" href="https://igem.org/2019_Judging_Form?team=Tuebingen" target="_blank" | ||
| − | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">JUDGING | + | style="font-family: 'Righteous', cursive; font-weight: normal; color: #2ecc71;">JUDGING FORM ⇗</a> |
| − | + | ||
</li> | </li> | ||
| Line 10,425: | Line 10,487: | ||
<div id="videoBox" class="text-center" style="position: relative; min-height:5%; width:100%; margin-top: 50px"> | <div id="videoBox" class="text-center" style="position: relative; min-height:5%; width:100%; margin-top: 50px"> | ||
<video id="videoShow" playsinline autoplay muted id="myVideo" style="min-height:5%; width:100%; margin-top: 50px"> | <video id="videoShow" playsinline autoplay muted id="myVideo" style="min-height:5%; width:100%; margin-top: 50px"> | ||
| − | <source src="https://2019.igem.org/wiki/images/ | + | <source src="https://2019.igem.org/wiki/images/a/a0/T--Tuebingen--MovieLast-mov.mov" type="video/mp4" |
style="width: 100%;"> | style="width: 100%;"> | ||
Your browser does not support HTML5 video. | Your browser does not support HTML5 video. | ||
| Line 10,496: | Line 10,558: | ||
<p class="text-justify mobileText"> | <p class="text-justify mobileText"> | ||
| − | “To fight the global | + | “To fight the global Diabetes pandemic, we would ideally have an accessible cost-effective |
easily-compliant intervention that has high clinical efficacy and that is free of adverse side | easily-compliant intervention that has high clinical efficacy and that is free of adverse side | ||
effects.”<br><br> | effects.”<br><br> | ||
| Line 10,535: | Line 10,597: | ||
<p class="text-justify mobileText">This enables an easier therapy where a regular intake of | <p class="text-justify mobileText">This enables an easier therapy where a regular intake of | ||
| − | medicals | + | medicals is not required.</p> |
<p class="text-justify mobileText">Improved cell penetrating peptides with the use of | <p class="text-justify mobileText">Improved cell penetrating peptides with the use of | ||
| Line 10,604: | Line 10,666: | ||
<div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | ||
<h2 class="display-4 mobileTitle" style="overflow-x: visible; font-family: 'Righteous';color:#2ecc71;"> | <h2 class="display-4 mobileTitle" style="overflow-x: visible; font-family: 'Righteous';color:#2ecc71;"> | ||
| − | An in depth E.coli Nissle characterization</h2> | + | An in depth <i>E. coli</i> Nissle characterization</h2> |
| − | <p class="text-justify mobileText">Despite the fact that E. | + | <p class="text-justify mobileText">Despite the fact that <i>E. coli</i> Nissle is an already |
approved probiotic, it's surprisingly badly characterized.</p> | approved probiotic, it's surprisingly badly characterized.</p> | ||
<p class="text-justify mobileText"> | <p class="text-justify mobileText"> | ||
| − | Hence, we provide the first metabolic model of E. coli Nissle and optimize it's growth for various | + | Hence, we provide the first metabolic model of <i>E. coli</i> Nissle and optimize it's growth for various |
| − | growth media. Furthermore, we predicted the interaction and competition of E. coli Nissle with | + | growth media. Furthermore, we predicted the interaction and competition of <i>E. coli</i> Nissle with |
common competitors for various fluxes in the gut. | common competitors for various fluxes in the gut. | ||
</p> | </p> | ||
<p class="text-justify mobileText"> | <p class="text-justify mobileText"> | ||
| − | Finally, we carried out a series of RNA-Seq experiments to assess the adaptions and reactions of E. | + | Finally, we carried out a series of RNA-Seq experiments to assess the adaptions and reactions of <i>E. |
| − | coli | + | coli</i> |
Nissle to aerobic, as well as anaerobic occurring stress factors. | Nissle to aerobic, as well as anaerobic occurring stress factors. | ||
</p> | </p> | ||
| Line 10,682: | Line 10,744: | ||
background-size: cover; | background-size: cover; | ||
background-position: center; | background-position: center; | ||
| − | background-image: url("https:// | + | background-image: url("https://2019.igem.org/wiki/images/2/2a/T--Tuebingen--white_logo_animated.gif"); |
} | } | ||
| Line 11,081: | Line 11,143: | ||
</script> | </script> | ||
| − | <div class='container-fluid p-3' style="background-color: | + | <div class='container-fluid p-3' style="background-color: #919191;"> |
| − | + | <hr> | |
| − | + | <div class='row align-items-center'> | |
| − | + | <div class='col-6 col-md-2 sponsorLogo text-center'> | |
| − | + | <a href="https://www.stura-tuebingen.de/" target="_blank2"><img class="img-fluid" | |
| − | + | src="https://2019.igem.org/wiki/images/1/10/T--Tuebingen--stura_logo.png" | |
| − | + | style="max-height: 80px;"></a> | |
| − | + | </div> | |
| − | + | ||
| − | <a href="https://www.embl.de/" target="_blank2"><img class="img-fluid" | + | <div class='col-6 col-md-2 sponsorLogo text-center'> |
| − | + | <a href="https://www.kohlbacherlab.org" target="_blank2"><img class="img-fluid" | |
| − | + | src="https://2019.igem.org/wiki/images/9/99/T--Tuebingen--kohlbacher_logo.png" | |
| − | + | style="max-height: 80px;"></a> | |
| + | </div> | ||
| + | <div class='col-6 col-md-2 sponsorLogo text-center'> | ||
| + | <a href="https://www.dieter-schwarz-stiftung.de/homepage.html" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/8/86/T--Tuebingen--LogoDSS.png" | ||
| + | style="max-height: 80px;"></a> | ||
| + | </div> | ||
| + | |||
| + | <div class='col-6 col-md-2 sponsorLogo text-center'> | ||
| + | <a href="https://www.embl.de/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/c/c4/T--Tuebingen--embl_logo.png" | ||
| + | style="max-height: 80px;"></a> | ||
| + | </div> | ||
| + | |||
| + | <div class='col-6 col-md-2 sponsorLogo text-center'> | ||
| + | <a href="https://www.experimenta.science/en/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/e/eb/T--Tuebingen--Logo-Experimenta.png" | ||
| + | style="max-height: 80px;"></a> | ||
| + | </div> | ||
| + | |||
<div class='col-6 col-md-2 sponsorLogo text-center'> | <div class='col-6 col-md-2 sponsorLogo text-center'> | ||
| − | + | <a href="https://www.medizin.uni-tuebingen.de/de/medizinische-fakultaet/forschung/core-facilities/ncct" | |
| − | + | target="_blank2"><img class="img-fluid" | |
| − | + | src="https://2019.igem.org/wiki/images/e/ec/T--Tuebingen--NCCT.png" | |
| − | + | style="max-height: 80px;"></a> | |
| + | </div> | ||
| + | |||
</div> | </div> | ||
| − | <div class='col- | + | |
| − | + | <hr> | |
| − | + | <div class='row align-items-center'> | |
| − | + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | |
| + | <a href="https://www.lexogen.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/4/43/T--Tuebingen--lexogen_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.zmbp.uni-tuebingen.de/zmbp.html" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/d/d8/T--Tuebingen--zmbp_logo.png" | ||
| + | style="max-height: 80px;"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="http://s466755640.online.de/4bl/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/0/0b/T--Tuebingen--4base_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.agilent.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/e/e7/T--Tuebingen--agilent_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.digitalocean.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/6/67/T--Tuebingen--digitalocean_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://dwk.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/c/ce/T--Tuebingen--dwk_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.eppendorf.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/a/a6/T--Tuebingen--eppendorf_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.implen.de/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/b/bb/T--Tuebingen--Logo-Implen.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.jenabioscience.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/3/31/T--Tuebingen--JBS_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.gbo.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/a/ae/T--Tuebingen--greiner_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="http://www.metabion.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/4/41/T--Tuebingen--Logo-Metabion.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.microsynth.ch/home-ch.html" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/1/18/T--Tuebingen--microsynth_logo.png"></a> | ||
| + | </div> | ||
</div> | </div> | ||
| − | <div class='col-6 col-md-2 sponsorLogo text-center'> | + | |
| − | <a href="https://www. | + | <div class='row align-items-center'> |
| − | + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | |
| − | + | <a href="https://www.neb.com/" target="_blank2"><img class="img-fluid" | |
| + | src="https://2019.igem.org/wiki/images/2/29/T--Tuebingen--neb_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.promega.de/en/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/f/f8/T--Tuebingen--promega_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.qiagen.com/us/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/9/92/T--Tuebingen--qiagen_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.carlroth.com/en/en" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/6/61/T--Tuebingen--roth_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.sitoolsbiotech.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/3/31/T--Tuebingen--sibiotools_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.snapgene.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/3/3a/T--Tuebingen--snapgene_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.trilinkbiotech.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/b/b6/T--Tuebingen--trilink_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://twistbioscience.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/4/4c/T--Tuebingen--Logo-Twist.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="http://www.vazymebiotech.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/b/b7/T--Tuebingen--vazyme_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.biolegend.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/c/c3/T--Tuebingen--biolegend_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.zymoresearch.de/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/6/6e/T--Tuebingen--zymo_logo.png"></a> | ||
| + | </div> | ||
| + | <div class='col-4 col-md-2 col-xl-1 sponsorLogo text-center'> | ||
| + | <a href="https://www.eurofins.com/" target="_blank2"><img class="img-fluid" | ||
| + | src="https://2019.igem.org/wiki/images/c/cd/T--Tuebingen--eurofins_logo.svg"></a> | ||
| + | </div> | ||
| + | |||
</div> | </div> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
</div> | </div> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
</html> | </html> | ||
Latest revision as of 20:24, 21 October 2019
GLP.exe - a safe and effective treatment for Type 2 Diabetes Mellitus
Several treatment options for Type 2 Diabetes Mellitus have been developed in recent years significantly improving the patients' insulin level.
Hence, the diagnosis of Type 2 Diabetes Mellitus is no longer a death sentence.
Current Drugs
are expensive, require fine tuning and daily shots. Moreover, they have severe side-effects, causing patients to skip doses.
“Many patients don’t want to use insulin. They don’t want
to do finger sticks and they’re afraid of hypoglycemia.”
“To fight the global Diabetes pandemic, we would ideally have an accessible cost-effective
easily-compliant intervention that has high clinical efficacy and that is free of adverse side
effects.”
Prof. Harold Lebovitz, State University of New York Health Science Center, Brooklyn, New York
However...
There's a solution!
Our therapeutic agent is a probiotic secreting incretin mimetics placed in the patients intestine by oral administration of capsules. GLP-1 and Exendin-4, our main actors, cause an increase in insulin secretion, if the cell has already taken up sugar.
This enables an easier therapy where a regular intake of medicals is not required.
Improved cell penetrating peptides with the use of artificial intelligence allow for an efficient and safe transport of our effectors into the cells.
Safety
is our highest priority!
Therefore, we developed a novel, Cas3 based kill-switch mechanism. The flexible system uses three regulators inspired by the human intestines: temperature, availability of fatty acids in form of Acyl CoA and N-Acetyl-Glucosamin.
If the conditions of our regulatory system are no longer met, Cas3 will be degrading all genetic information.
Additionally
An in depth E. coli Nissle characterization
Despite the fact that E. coli Nissle is an already approved probiotic, it's surprisingly badly characterized.
Hence, we provide the first metabolic model of E. coli Nissle and optimize it's growth for various growth media. Furthermore, we predicted the interaction and competition of E. coli Nissle with common competitors for various fluxes in the gut.
Finally, we carried out a series of RNA-Seq experiments to assess the adaptions and reactions of E. coli Nissle to aerobic, as well as anaerobic occurring stress factors.
Our work lays the foundation for an innovative, unprecedented approach to treat Type 2 Diabetes Mellitus.
